All lobbying filings

TEVA PHARMACEUTICALS USA, INC.

Lobbying for TEVA PHARMACEUTICALS USA INC

Filing 1st Quarter - Report

1st Quarter (Jan 1 - Mar 31) 2026 · New Jersey · House · Senate · $1,100,000.00 expenses · posted Apr 20, 2026

Official filing document

Bills named in this filing 3

SJRES 37
A joint resolution terminating the national emergency declared to impose duties on articles imported from Canada.
S 959
Tariff Transparency Act of 2025
HR 6888
Trump Tariff Transparency Act

Lobbying activity 2

Health Issues

Use of Section viii statements in pharmaceutical labeling. Changes to Hatch-Waxmans 180-day exclusivity incentive. Changes to FDA approval process for pharmaceuticals. Implementation of the Inflation Reduction Act. Drug pricing proposals. Oversight and legislation to reform pharmacy benefit managers. Patent reform legislation. Proposals related to drug shortages. Reauthorization of the Pandemic and All Hazards Preparedness Act (PAHPA). Proposals related to biosimilar drugs.

Tariff (miscellaneous tariff bills)

A joint resolution terminating the national emergency declared to impose duties on articles imported from Canada (S.J.Res.37). Tariff Transparency Act of 2025 (S.959) and Trump Tariff Transparency Act (H.R.6888).

Source: federal Lobbying Disclosure Act filing. Bills are parsed from the activity descriptions.